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Abstract
Background: Patients, clinicians, researchers and payers are seeking to understand the value of using genomic
information (as reflected by genotyping, sequencing, family history or other data) to inform clinical decision-
making. However, challenges exist to widespread clinical implementation of genomic medicine, a prerequisite
for developing evidence of its real-world utility.
Methods: To address these challenges, the National Institutes of Health-funded IGNITE (Implementing GeNomics
In pracTicE; www.ignite-genomics.org) Network, comprised of six projects and a coordinating center, was established
in 2013 to support the development, investigation and dissemination of genomic medicine practice models that
seamlessly integrate genomic data into the electronic health record and that deploy tools for point of care decision
making. IGNITE site projects are aligned in their purpose of testing these models, but individual projects vary in scope
and design, including exploring genetic markers for disease risk prediction and prevention, developing tools for using
family history data, incorporating pharmacogenomic data into clinical care, refining disease diagnosis using sequence-
based mutation discovery, and creating novel educational approaches.
Results: This paper describes the IGNITE Network and member projects, including network structure, collaborative
initiatives, clinical decision support strategies, methods for return of genomic test results, and educational initiatives for
patients and providers. Clinical and outcomes data from individual sites and network-wide projects are anticipated to
begin being published over the next few years.
Conclusions: The IGNITE Network is an innovative series of projects and pilot demonstrations aiming to
enhance translation of validated actionable genomic information into clinical settings and develop and use
measures of outcome in response to genome-based clinical interventions using a pragmatic framework to
provide early data and proofs of concept on the utility of these interventions. Through these efforts and
collaboration with other stakeholders, IGNITE is poised to have a significant impact on the acceleration of
genomic information into medical practice.
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Background
The potential benefits of genomic medicine, or the use of
an individual patient’s genomic information (as reflected
by family history, genotyping, sequencing or other DNA-
based technology) into clinical decision making, are in-
creasingly being recognized. Challenges to clinical imple-
mentation of genomic medicine have been identified at
multiple levels including limited availability of evidence
for clinical utility; ‘genomic unfamiliarity’ of providers, pa-
tients and families; limited access to advanced genetic test-
ing and ambiguity of result interpretation; lack of
reimbursement for genetic testing; and the need for real-
time, point-of-care integration of test results with the elec-
tronic health record (EHR) and clinical decision support
(CDS) tools. [8] Overcoming these challenges on a large
scale will require collaborative efforts to develop effective
health care delivery models of genomic medicine; demon-
strate potential benefits of genomic data to improve pa-
tient outcomes and quality of care, and reduce costs of
care; provide tools to support successful integration of
genomic data in a platform-agnostic EHR environment;
use CDS to facilitate streamlined and efficient care; and
engage and educate providers, patients and payers in an
efficient and effective manner. To support development
and investigation of such practice models, the National
Human Genome Research Institute (NHGRI) invited re-
searchers to develop methods for, and evaluate feasibility
of, incorporating an individual patient’s genomic findings
into his or her clinical care. As a result, the IGNITE
(Implementing GeNomics In pracTicE; www.ignite-geno-
mics.org) Network was established with three initial sites
and a coordinating center (CC) in 2013; three additional
sites were added to the network one year later (Fig. 1).
Methods
The goals of the IGNITE network are to 1) expand
and link existing genomic medicine implementation
efforts; 2) develop new collaborative projects and
methods for genomic medicine implementation in di-
verse settings and populations; 3) contribute to the
evidence base of outcomes following the use of gen-
omic information for clinical care; and 4) define,
share and disseminate the best practices of genomic
medicine implementation, diffusion and sustainability
in diverse settings. Each site participating in the NIH-
funded IGNITE Network is developing and testing a
clinical model for implementing genomic information
(including diagnostic refinement, disease risk assess-
ment, pharmacogenomic and family history data) into
patient care with incorporation of the genomic infor-
mation into the EHR and measures of outcomes in
response to a genomic medicine intervention. In
addition, sites are developing novel patient and pro-
vider educational models; testing CDS strategies to
support clinical use of genomic data; utilizing novel
dissemination and sustainability methods; and collect-
ing data on factors influencing adoption of genomic
medicine. All IGNITE projects are also examining im-
plementation across a broad range of practice envi-
ronments, including academic and non-academic
settings as well as among diverse socio-economic and
demographic patient populations.
IGNITE network members
The IGNITE Network consists of six member projects
and a Coordinating Center which along with NHGRI
program staff comprise the governing Network Steering
Fig. 1 Legend: IGNITE Network Site Locations (Available at: http://www.genome.gov/27554264)
Weitzel et al. BMC Medical Genomics  (2016) 9:1 Page 2 of 13
Committee (Fig. 2). Each of the six IGNITE network
projects are based in academic medical centers in part-
nership with a broad range of health systems with pri-
mary focus on health care delivery. Thus, the IGNITE
Network is uniquely positioned to advance genomic
medicine in a ‘real-world’ health care delivery framework
with broad public health relevance. Although all IGNITE
projects are aligned in their purpose of developing and
testing clinical models for integrating genomic informa-
tion into patient care, individual projects vary widely in
their design and scope. Thus the results from these pro-
jects will form a broad foundation for implementation of
genomic medicine. IGNITE members will not only ad-
vance the science of genomic medicine through their fo-
cused projects, but also by comparing strategies, sharing
information and collaborating across projects (Table 1).
Individual IGNITE projects are described below.
Duke University - implementation, adoption and utility of
family history in diverse care settings
Background Family health history (FHH) assessments
have clearly been shown to identify persons at higher
risk for common chronic disease, enabling preemptive
and preventive steps, including lifestyle changes, health
screenings, testing and early treatment as appropriate
[5]. More recently Qureshi has shown prospectively the
potential to identify presymptomatic individuals at ele-
vated risk for common, chronic diseases and activate
them to modify their risks [11] - an enormous opportun-
ity to improve public health by implementing risk-based
screening and prevention strategies. Yet, although FHH
is a standard component of the medical interview and
professional guidelines recommend screening strategies
based upon FHH, its widespread adoption is hindered by
three major barriers: (1) standard collection methods; (2)
health care provider access to FHH information; and (3)
clinical guidance for interpretation and use of FHH. The
Duke University FHH project utilizes MeTree™, a plat-
form that collects FHH directly from the patient and
provides CDS to providers with guidelines-based recom-
mendations for individuals at high risk for developing a
common chronic disease.
Overview This project utilizes a Genomic Medicine
Model (GMM) developed in the context of the MeTree™
FHH pilot led by Duke University (https://precisionmedi-
cine.duke.edu). The GMM is a novel flexible and
Fig. 2 Legend: Organizational Structure of the IGNITE Network
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Table 1 Comparison of CDS, Return of Results and Educational Strategies for IGNITE Projects
Site/Project Characteristics of CDS Return of results Educational strategies
Duke University: Implementation,
Adoption and Utility of Family
History in Diverse Care Settings
• Open source (OpenCDS)
• Bidirectional
• Based on HL7 Virtual Medical Record
standard
• Epic-based system
• Directly to patients and providers via CDS
within the EHR
• English and Spanish language versions of
FHH software
• Printed and web based materials
• Patient workbook and instructions for capturing FHH
• Patient report for FHH results
Indiana University - INGenious:
INdiana Genomics Implementation:
an Opportunity for the UnderServed
• Eskenazi home-grown EHR system
• Automated identification and
randomization of patients
• Capture of genetic variant data
and reporting into EHR
• Automatic alerts
• Links to guidelines and supporting
evidence for patients with
pharmacogenomic results
• Directly to providers via CDS within the EHR • Personal engagement with Eskenazi patient
representative organization
• Print materials in language-appropriate form
in clinics
Icahn School of Medicine at Mount
Sinai - Genetic testing to Understand
and Address Renal Disease
Disparities (GUARDD)
• Epic-based system that incorporates CLIPMERGE
• Alert-based informed message for provider that
integrates EHR and allele data
• Based on HL7 standards• Integrated with Redcap
• CDS alert includes link to provider and patient
education materials
• Directly to providers via CDS within the EHR
• To patients by research staff trained by genetic
counselors
• Genetic counselor available for consultation with
patients or research staff
• Print materials (low-literacy, culturally appropriate,
co-developed with community leaders and
APOL1-positive patients) provided to patients at
return of result and available for download
by clinicians
University of Florida – UF Health
Personalized Medicine Program
• Epic-based system
• Alert-based informed message for provider
that integrates EHR and allele data
• Integrated with Redcap
• CDS alert includes link to patient education
materials
• Directly to providers via CDS within the EHR • Print and online materials for patients and clinicians
• Continuing education and academic courses for
health care professionals and students
University of Maryland - Genomic
Diagnosis and Personalized Therapy
for Highly Penetrant Genetic
Diabetes
• Epic-based system
• Interface of screening tool and algorithm with
EHR to produce alert for testing
• Integration of actionable result report into EHR
• Genetic result-based diagnosis/treatment
recommendation alerts
• Direct communication of results to patients and
entry into medical record
• Customized materials provided to patients for
communicating with other family members
• If a variant of unknown significance is found,
patients will be informed and invited to participate
in additional research
• In-person throughout the study process (e.g., patient
informed consent conducted by genetic counselor
and research coordinator)
• For patients with a pathogenic variant, study team
and provider will discuss implications
• Print materials also provided to patients
throughout study
Vanderbilt University - Integrated,
Individualized and Intelligent
Prescribing (I3P) Network
• Multiple EHR systems (Epic, Veterans Affairs CPRS,
McKesson, home-grown)
• Bidirectional
• Based on HL7 standards
• Incorporates newly developed HL7 genomic
data standard
• Include interpretative recommendations
• Link out to external information sources
(e.g., MyCancerGenome.org)
• Passive and active alerts
• Directly to providers via CDS within the EHR • Print and online materials for patients and clinicians
• Integrated with CDS
• Provider focus groups














adaptable model, with three components, designed to
overcome barriers in the implementation of personalized
medicine: 1) education of physicians and patients; 2) a
health IT-based FHH platform, MeTree™, that collects
FHH directly from patients on the front end and generates
individualized risk-stratified evidence-based preventive
care recommendations for physicians (as well as a pedi-
gree and patient-oriented recommendations) on the back
end, and 3) CDS to effectively interpret FHH information
and carry out recommendations.
The IGNITE FHH project is a real-world interven-
tion and outcomes study implemented in 28 primary
care practices across 5 major health care delivery sys-
tems in the United States: Duke Health System, Med-
ical College of Wisconsin, Essentia Health, University
of NorthTexas Health Science Center, and the United
States Air Force. Study sites include urban, suburban
and rural settings serving a balance of minorities,
women and socioeconomic statuses. Primary care
practices at each site are assigned to use the MeTree™
FHH intervention and others, matched on practice
demographics, perform usual care without it and serve
as controls. Investigators are developing an open-
source, standards-based CDS resource for FHH that
will create EHR-enabled tools and CDS, with FHH
data elements defined in the context of the HL7 Vir-
tual Medical Record standard. This OpenCDS ap-
proach will provide a prototype for dissemination of
evidence-based algorithms to EHRs to both patients
and providers.
The goals of the Duke University FHH project are to
1) develop an optimal strategy for implementing
MeTree into routine clinical practice in diverse settings;
2) demonstrate the effectiveness of MeTree in increas-
ing uptake of risk-stratified evidence-based prevention
guidelines; 3) create a standardized family health his-
tory storage database that can integrate with electronic
medical records for bi-directional communication of
family and personal history data and risk assessment re-
sults, and 4) disseminate guidelines for a FHH interven-
tion in diverse practice settings.
Outcomes The outcome measures for this project include
patient, provider and system effects in the following
domains: emotional (e.g., quality of life, satisfaction); be-
havioral (e.g., adherence, workflow processes); biological
(e.g., demographics, FHH); clinical (e.g., laboratory data,
patient population characteristics); and financial (e.g.,
socioeconomic status, medication costs). In addition,
implementation measures include model reach, effect-
iveness, adoption, implementation integrity, implemen-
tation exposure and maintenance and sustainability of
the intervention.
Icahn School of Medicine at Mount Sinai - Genetic Testing
To Understand And Address Renal Disease Disparities
(GUARDD)
Background Chronic kidney disease (CKD) is com-
monly associated with hypertension (28 %) and affects
26 million American adults. Most cases of hypertension
are managed by primary care providers. African ancestry
populations with hypertension (HTN) have 2- to 3-fold
higher risk of developing CKD, and a 5-fold increased
risk to progress to end stage renal disease (ESRD) when
compared with whites. HTN is a risk factor for progres-
sion of CKD and for increased cardiovascular disease
(CVD) risk with CKD. Thus targeting blood pressure con-
trol as a modifiable risk factor may both reduce CVD in
people with CKD and reduce progression of CKD to end
stage disease. Recent discoveries demonstrate that testable
alleles of the APOL1 locus on chromosome 22 have a
major effect on and explain most of the excess risk for
hypertension associated CKD and its progression to ESRD
in African ancestry populations. Hypertension-associated
CKD in African Ancestry populations has emerged as a
highly relevant and well-suited opportunity for a ‘proto-
type’ genomic medicine demonstration project for com-
mon chronic illnesses managed in primary care settings.
Overview The GUARDD study is designed to generate
essential insights for sustainable adoption and large-
scale dissemination of genomic medicine in diverse
clinical settings providing care for common adult-onset
diseases in general, and for underserved African Ances-
try populations with large excess burden of non-
diabetic kidney diseases specifically. Investigators are
using community-engaged approaches to enroll 2050
patients of African Ancestry at primary care facilities of
the Mount Sinai Health System and of the Institute for
Family Health, a network of community health centers
with 13 sites in New York City. Patients must be 18–70
years of age, a patient at a participating care site, self-
report African American/Black race and have a history
of hypertension with no history of diabetes or kidney
disease. Eligible patients will be randomized to an inter-
vention or a control group in a seven-to-one ratio
where APOL1 genetic testing and return of results will
be offered at the beginning or at the end of a 1-year
evaluation period, respectively. The intervention group
will be stratified naturally by APOL1-positive (increased
genetic risk) and APOL1-negative (population-average
genetic risk) genetic test results. Patients will be in-
formed about their genetic risk status and its implica-
tions for their healthcare by trained study coordinators.
Their providers will receive CDS stratified by APOL1-
positive or -negative results in form of best practice
alerts displayed at the beginning of encounters with
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enrolled patients. In addition to clinical follow-up data
available through EHR data mining, standardized re-
search data will be collected through clinical testing
and questionnaires administered by study coordinators
at 3 and 12-month follow-up visits.
Outcomes Primary outcome measures will be compared
among three arms of the GUARDD study, including
APOL1-positive (estimated N ~ 250) and APOL1-negative
(estimated N ~ 1550) intervention groups and the control
group without intervention (estimated N ~ 250). Primary
outcome measures include 1) change in systolic blood
pressure and 2) utilization of blood and urine tests to as-
sess kidney function in the APOL1-positive group com-
pared with APOL1-negative group and control group at 3
and 12 months. Secondary endpoints will include compre-
hensive provider- and patient-oriented survey outcomes
and process measures.
Indiana University - INGENIOUS: INdiana Genomics
Implementation: an Opportunity for the UnderServed
Background Genomic-based interventions such as phar-
macogenomic testing have the potential to improve pa-
tient outcomes and reduce health care system costs. This
could occur by reduction of adverse drug reactions and
their associated medical costs, through the improvement
of drug efficacy for expensive health care conditions, or by
the targeting of effective, but expensive therapies to those
most likely to benefit. Measurement of such costs is chal-
lenging, and not possible without an informatics infra-
structure capable of measuring both financial costs and
clinical outcomes. As a result, the business case for imple-
mentation of genomic and pharmacogenomics testing in
large health care systems has not been persuasive.
Overview Indiana University School of Medicine and
the Indiana University Institute for Personalized Medi-
cine in collaboration with the Eskenazi Health System
are conducting a study to evaluate the economic and
clinical outcomes associated with embedding a pharma-
cogenomics program in a system that serves as a health
care safety-net in Indianapolis, Indiana. The INGenious
project is a prospective, randomized, trial enrolling a
total of 6000 patients, with 2000 patients assigned to a
pharmacogenetic testing arm and 4000 to a control arm
who will be followed, but not tested. A pharmacogenetic
test, involving 51 SNPs in 16 genes will be carried out at
the beginning of the study in patients in the testing arm
upon prompting by an index medication: one of 24 se-
lected as being supported by validated guidelines. This
study is randomized between an intervention arm and one
that receives no intervention in order that a genotyped
group can be compared with one in which undisturbed,
routine clinical care is carried out in patients taking the
same drugs. Both arms will be followed for one year.
The specific aims of the INGENIOUS project include:
1) testing whether Clinical Laboratory Improvements
Amendment (CLIA)-certified genotyping that is tar-
geted at 24 widely used drugs is associated with signifi-
cant reductions in hospital and outpatient economic
costs incurred over 1 year; and 2) determining whether
pharmacogenetic testing is associated with significant
improvements in clinical outcomes over 1 year.
Outcomes The INGENIOUS project is comparing the
following outcomes between the two study arms: a)
hospital and outpatient economic costs incurred over
1 year; and b) clinical outcomes over 1 year. Cost data
are being obtained from patients randomized to either
arm of the trial. The categories of inpatient and out-
patient charges collected include medication, pharmacy,
facility, laboratory test, treatment, professional and
others. Clinical outcomes data being collected from the
Eskenazi informatics system include the number of ad-
missions, the number of emergency department visits,
the number of clinic visits and returns to clinic. In
addition, data are being collected on adverse drug reac-
tion diagnostic codes and changes in drug regimens
(according to prescribing patterns and the Medication
Possession Ratio (MPR) of index medications).
University of Florida – UF Health Personalized Medicine
Program
Background There is substantial evidence that both ef-
ficacious and adverse responses of many drugs are sig-
nificantly influenced by genetic variability. There are
numerous examples of clinically actionable variants in
pharmacogenetics and 10 % of all drugs contain phar-
macogenetic information in their FDA-approved prod-
uct label [14]. Nonetheless, there are limited examples
of translation to practice in pharmacogenetics, making
it an obvious starting point for implementation of gen-
omic medicine.
Overview The University of Florida (UF) Health Per-
sonalized Medicine Program (PMP, http://personalized-
medicine.ufhealth.org/) is a multidisciplinary clinical
initiative to implement genomic medicine, with the
program built around the long-term perspective that
large amounts of genomic data are likely to be available
on patients in the future. While the long-term goal of
the PMP is to include disease risk prediction and
defining disease prognosis, the initial focus is on imple-
menting pharmacogenetics to guide drug decisions in
clinical practice. [16].
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The UF Health PMP IGNITE project builds on the
existing framework for clinical pharmacogenomics already
in place at UF Health, launched in 2011. Within this pro-
gram, CYP2C19-guided clopidogrel therapy was initiated
in 2012 and additional gene-drug pairs have subsequently
been implemented clinically. [16]. UF Health PMP’s IG-
NITE project has 3 broad aims. The first aim is to expand
and evaluate the clinical implementation of pharmacoge-
netic information to guide treatment decisions at UF
Health. Specific drug-gene implementations are driven by
the strength of the evidence, and potential impact on pa-
tient care in the specific patient population, with priorities
set to some degree by interest/demand from clinicians
within the health system. The second aim seeks to docu-
ment that such a program can be successfully imple-
mented outside a tertiary care university health system.
This aim will focus on implementing in community prac-
tices and hospitals, with one of the goals being to identify
the challenges that are common and unique between the
UF Health implementations, and implementation in other
setting. The third aim is focused on educational programs
targeted at health sciences students, practicing clinicians
and patients or the lay public. It is recognized that a sig-
nificant barrier to implementation is knowledge of the
area and comfort level among practicing clinicians with
using genetic information to guide clinical decisions, and
the innovative educational programs, which include the
opportunity for the individual to receive personal geno-
type information to use during the educational activity,
seek to help overcome these barriers.
Outcomes Implementation metrics (e.g., test adoption
rate, workflow processes, drug therapy changes initiated
after test results) are being collected within and outside
the UF Health system for all implementations. Clinical
outcomes are being tracked either retrospectively (e.g.,
major adverse cardiovascular event rates in CYP2C19-
clopidogrel patients) or prospectively (e.g., assessment of
pain intensity, physical and emotional functioning with
CYP2D6-codeine, tramadol patients). Knowledge, atti-
tude and beliefs of educational program participants are
also being assessed before and after completion of the
educational activity.
University of Maryland - genomic diagnosis and
personalized therapy for highly penetrant genetic diabetes
Background Diabetes mellitus, a heterogeneous group of
diseases characterized by hyperglycemia, affects over 25
million individuals in the United States and is a leading
cause of cardiovascular disease, blindness, end-stage renal
disease and death. Highly penetrant genetic forms of dia-
betes account for at least 1 % of diabetes, or over 250,000
cases nationwide. The most well-known and apparently
most common highly penetrant genetic forms are trad-
itionally known as “maturity onset diabetes of the young,”
or MODY, which is most often caused by mutations in
genes encoding pancreatic beta cell transcription factors
or glucokinase. Several other syndromic and nonsyn-
dromic forms of diabetes are caused by a single gene mu-
tation. Distinguishing highly penetrant genetic forms of
diabetes from the more common classes of diabetes, type
1 diabetes (T1DM) and type 2 diabetes (T2DM) often
directly leads to more personalized and therefore more
effective treatment, more accurate prediction of prognosis
and familial risk assessment. Given these benefits, the
American Diabetes Association (ADA) recommends that
testing for monogenic diabetes be considered in several
situations in children [1], but does not currently offer a
specific algorithm for screening or testing and does not
offer recommendations for screening adults.
Overview This demonstration project will address the
gap in monogenic diabetes detection and advance the
implementation of genomic medicine in diabetes care
by developing a real-world approach and EHR-compatible
tools that can be disseminated broadly to improve screen-
ing, diagnosis and treatment of patients with highly pene-
trant genetic diabetes and their family members. In
addition, the Personalized Diabetes Medicine Program
(PDMP) will provide a model for finding and diagnosing
highly penetrant genetic forms of other common diseases
whose genetic architecture mirrors that of diabetes such
as Alzheimer’s disease, Parkinson’s disease, cardiovascular
disease and cancer.
First, this project will further develop the PDMP at the
University of Maryland Center for Diabetes and Endo-
crinology and expand the Program into family medicine
clinics and other partner centers (i.e., Baltimore Veterans
Administration Medical Center, Geisinger Health System
and Bay West Endocrinology Associates), and the larger
community through extended site visits and media com-
munications. The PDMP comprises an efficient screen-
ing tool to identify patients with diabetes who are strong
candidates for having highly penetrant genetic forms of
diabetes, a diagnosis algorithm that includes clinical and
laboratory data, a novel highly penetrant genetic diabetes
gene sequencing panel (40–55 genes), incorporation of
genetic results into the electronic health record, and
treatment recommendations customized to the genetic
diagnosis.
This project also includes an evaluation of effects of
implementing systematic screening and molecular diagno-
sis and treatment of highly penetrant forms of diabetes on
clinical and patient-reported outcomes, resource utilization
and barriers and facilitators of dissemination across di-
verse patient populations and healthcare delivery sys-
tems. Finally, a payer advisory panel is being engaged in
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the development of the impact evaluation process to
enhance investigators ability to collect meaningful evi-
dence to inform clinical practice recommendations and
guide insurance coverage decisions.
Outcomes The primary clinical outcome will be changes
in HbA1c and blood glucose, with other clinical mea-
sures including changes in albuminuria, serum lipids,
hypoglycemic episodes, weight change and visits to
the clinic or emergency room. Effects of receiving or
not receiving a molecular diagnosis and undergoing
or not undergoing a treatment change will be evalu-
ated. Data on multidimensional aspects of physical,
mental and psychosocial aspects of health will be col-
lected using validated instruments. Development of
other patient-reported and patient-centered outcomes
are being guided by the Payer Advisory Panel. Quali-
tative data regarding potential benefits and concerns
raised by the intervention will also be collected as
well as the potential impact of the intervention for
at-risk family members.
Vanderbilt University - Integrated, Individualized and
Intelligent Prescribing (I3P) Network
Background The purpose of the I3P project is to perform
a multisite test of the hypothesis that integrating genetic
data within environments with diverse EHRs and inform-
atics capabilities is feasible and can alter physician behav-
ior toward a vision of individualized medicine. I3P is based
on two, large-scale quality improvement initiatives for
genome-based prescribing already in place at Vanderbilt,
both launched in 2010. The Personalized Cancer Medicine
Initiative (PCMI) provides routine, multiplexed tumor
gene mutation testing for patients with various cancer
diagnoses, including non-small cell lung cancer (NSCLC)
and melanoma.[12, 13] The Pharmacogenomic Resource
for Enhanced Decisions In Care and Treatment (PRE-
DICT) program provides the organizational framework,
technical infrastructure and institutional processes to
allow clinically useful germline genotypes to be deposited
into the Vanderbilt EHR and used in clinical care through
electronic decision support.[10] Opportunities for
genome-guided care are common – among the first
10,000 patients in PREDICT, 91 % of European ancestry
individuals and 96 % of African ancestry individuals
had actionably variants among five drug-genome inter-
actions implemented in PREDICT, and the multiplexed
genetic testing model used in PREDICT resulted in 35 %
fewer tests than a traditional single drug-gene pair
models.[15] For both PREDICT and PCMI, structured,
computable variant data are decoupled from the interpret-
ation of their clinical significance.
Overview I3P will utilize existing, consensus-based phar-
macogenomic knowledge in the creation of new technolo-
gies which provide shared clinical decision support to
disparate external systems. Specifically, this project lever-
ages the knowledge gained from PREDICT and PCMI to
incorporate germline and somatic genomic testing and
CDS at four external sites: Nashville Veterans Affairs
Medical Center (NVAMC); Nashville General Hospital/
Meharry Medical College (MMC); Aurora Health Care
(AHC); and at Sanford Health (SH). The healthcare sys-
tems selected for this pilot effort, which use three different
EHRs, include underserved minority and military popula-
tions and a community health system. NVAMC utilizes
the Computerized Patient Record System (CPRS), which
is in place at 152 VA medical centers and covers 8 million
veterans. AHC and SH use Epic across 15 hospitals. MMC
primarily serves an underserved population and employs
different EHR systems for the inpatient and outpatient
environments, requiring integration across both. Thus,
successful implementation of genetic data and decision
support modules will provide a model for translation to
a wide variety of healthcare systems with diverse EHR
ecosystems and informatics capabilities. Indeed, SH has
already implemented CDS for several germline drug-
genome interactions [7].
Three germline drug-gene pairs are being targeted for
I3P implementation: CYP2C19-clopidogrel, SLCO1B1-
simvastatin and VKORC1/CYP2C9-warfarin. In oncology,
genetic testing and decision support is being implemented
for erlotinib in the treatment of NSCLC and vemurafenib
for melanoma. Initial implementation will focus on clopi-
dogrel and erlotinib.
Outcomes The primary outcomes will be rates of
genome-tailored prescriptions at each site. As with the UF
Health IGNITE program, we will seek to evaluate anti-
platelet prescriptions based on CYP2C19 metabolizer
status. Retrospective evaluations will seek rates of major
adverse cardiac events based on genotype and prescription
status using automated electronic phenotype algorithms
applied to EHR data [4]. Similar evaluations of genome-
tailored prescriptions and dosage evaluation will be under-
taken for each drug-genome interaction implemented.
Implementation challenges vary based on sites differences:
a government-run VA, two large non-academic health sys-
tems, and a university paired with a local county hospital.
Additionally, we are finding that each EHR system poses
unique challenges to incorporation of genetic information
and sending a CDS alert. We will assess provider attitudes,
identifying key road blocks and processes for overcoming
these challenges, and develop technologies to facilitate
incorporation of computable representations of genomic
knowledge into diverse EHRs.
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Coordinating Center (CC) – University of Pennsylvania
The goal of the IGNITE CC is to support the success of
individual sites and stimulate collaboration across projects
to produce and disseminate generalizable knowledge.
Such knowledge can be used to sustain and expand exist-
ing efforts and to inform implementation in other clinical
settings.
To accomplish this goal, the CC collaborates with
study investigators and the NHGRI to coordinate, fa-
cilitate and support program activities at multiple
levels, including handling network administrative lo-
gistics (e.g., organizing meetings and conference calls),
developing and maintaining the IGNITE website, and
providing mechanisms for internal communications
among projects and with NHGRI. CC faculty co-
investigators contribute their expertise to the IGNITE
projects in the areas of medical genetics, genetic coun-
seling; statistical genetics; clinical decision support
tools; bioinformatics; outcomes measurement; epi-
demiology; clinical trials; and ethical, legal and social
issues in genomics. They work with IGNITE site in-
vestigators to address challenges, apply solutions and
conduct and facilitate cross-study analyses in order to
maximize the public health impact of these genomic
implementation studies.
The CC team uses the Consolidated Framework for
Implementation Research (CFIR; DAMSCHRODER et
al. 2009) to assist sites in informing the development of
their implementation interventions, assessing the ef-
fectiveness of these implementations, and improving
their chances of success, sustainability and dissemin-
ation. CFIR provides an overarching and flexible typ-
ology that can be applied to implementations to learn
what works and why across multiple contexts. The use
of a mutually agreed-upon framework helps guide each
step of the implementation process, e.g., identifying fac-
tors that promote or impede implementation, integrat-
ing genomic findings into electronic health records,
developing clinical decision support tools, and defining
and measuring outcomes of implementation
The specific aims of the CC thus are to: 1) support IG-
NITE projects through logistics planning, maintenance
of continuous dialogue and sharing across projects and
with NHGRI, identification of barriers and their solu-
tions, and dissemination of these solutions across all
sites and to the broader scientific community; and 2)
stimulate and leverage synergy across IGNITE and with
other initiatives to develop common themes of imple-
mentation, optimize return of results, develop and dis-
seminate detailed process and outcome measures, create
new generalizable knowledge, evaluate the efficacy and
effectiveness of implementation strategies, and develop
methods to sustain and expand the implementation of
genomics into clinical practice.
Network organization and governance
The IGNITE Network is organized into an executive
committee (Coordinating Center principal investigator,
Steering Committee Chair and NHGRI program staff )
and steering committee (IGNITE principal investigators
and NHGRI program staff ), that along with their co-
investigators, meet by conference call monthly and in-
person three times annually (Fig. 2). Leadership of the
steering committee rotates through principal investiga-
tors, who each serve a one-year term. The Coordinating
Center is responsible for network-wide communica-
tions and data and project management. Two working
groups spearheaded the initial network-wide projects
and data sharing initiatives: 1) the Common Measures
Working Group and 2) the Dissemination, Outreach,
Economics and Sustainability Working Group. Other
network-wide interest groups have subsequently been de-
veloped, including: 1) Pharmacogenomics; 2) Education;
3) CDS Development and Measures; 4) Provider and
Payer Adoption and Barriers; and 5) Clinical Validity and
Utility interest groups. A six-member External Scientific
Panel (ESP) provides independent input to NHGRI bi-
annually about network progress and direction.
Data collection
The IGNITE network is collecting various types of
data: clinical, family history, genetic and outcomes
(Table 2). Genomic data include individual patient gen-
etic and pharmacogenetic test results and family health
history data, including pedigree and personal risk as-
sessment reporting. Genetic testing that is being re-
ported to providers and patients is being conducted in
College of American Pathologists–Clinical Laboratory
Improvement Amendments (CAP–CLIA) certified clinical
laboratories (University of Florida, Indiana University,
University of Maryland, Mount Sinai and Vanderbilt); if
DNA samples are retained for further research purposes,
this is done in the research institution’s secured biobank
or biorepository facility. Family health history data are
maintained in a secure cloud server behind the Duke Uni-
versity firewall. Genetic and pharmacogenetic test results,
risk assessment reports based on family history and clin-
ical data, and health pedigrees are returned to the clinician
and/or patient via the EHR in the clinical process of care.
Although the clinical and patient outcomes measured vary
by project, all IGNITE sites anticipate that the patient’s
clinician will use the data that are returned to inform pa-
tient care decisions, per the IRB-approved protocols. The
goals of IGNITE are to determine whether these data im-
prove patient-specific outcomes, such as decreased ad-
verse effects with application of pharmacogenetics test
results, lower blood pressure with patient knowledge of
APOL1 genetic risk status, safer and more effective glu-
cose control or reduced glucose monitoring based on
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Table 2 IGNITE network strategies for data collection, distribution and use in patient care
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specific diabetes subtype diagnosis, or improved prevent-
ive care and screening based on individual knowledge of
family health history.
Results
Clinical and outcomes data from individual sites are an-
ticipated to begin being published over the next two
years, and in some cases, cross-network findings are
being assembled. For example, the outcomes data from
University of Florida’s clopidogrel-CYP2C19 implemen-
tation are being presented in abstract form (Weitzel K,
personal communication) and have led to a network-
wide project on outcomes associated with clinical imple-
mentation of CYP2C19-guided dual antiplatelet therapy.
Similarly, individual sites are sharing with one another
the critical challenges in implementation of genomics,
which is leading to opportunities both to advance the
field as a whole and to facilitate the groups learning
from one another. These broad challenges to clinical im-
plementation range from limitations in genotyping and
EHR capabilities to a wide variety of educational needs
as well as the development of practical strategies that
are applicable to diverse practice settings.
Many of the initial challenges that have been encoun-
tered broadly in clinical implementation have resulted
from real-world limitations in standardizing genotyping
platforms for clinical practice, storing genetic data in com-
putable formats, developing CDS capabilities, adapting
clinical strategies as evidence and technology rapidly de-
velop, and accessing outcomes data. IGNITE investigators
are working collaboratively with external partners and IG-
NITE affiliate members to develop real-world, scalable so-
lutions to these challenges that are informed by a broad
sampling of clinical practice settings. For example, the IG-
NITE Pharmacogenetics Interest Group is partnering with
in- and out-of-network sites to aggregate and analyze out-
comes data on the clinical utility of pharmacogenetic test-
ing for specific gene-drug pairs. The CDS Interest Group
is collaborating with eMERGE (https://emerge.mc.vander-
bilt.edu/) and other stakeholders to develop an online
CDS resource (http://CDSKB.org) that will support clin-
ical use of genomic data and its integration into the EHR.
The Clinical Validity and Utility Interest Group is working
to assess and document the clinical validity and clinical
utility and economic implications of the interventions to
ensure the sustainability of moving genomic medicine into
clinical practice.
Other barriers to implementation that have been
identified as being common to all IGNITE sites include
gaps in provider knowledge and education, limited clin-
ician experience with genetic testing and return of results,
the need for user-friendly practice-based resources, and
the need to educate widely variable target audiences.
IGNITE interest and working groups, including the
Education, Provider Adoption Barriers and Common
Measures, are developing tools to identify and assess
adoption barriers and are collaborating with other
stakeholders (e.g., Inter-Society Coordinating Commit-
tee for Practitioner Education in Genomics, Genetics
and Genomics Competency Center, eMERGE) to cre-
ate and disseminate easily-accessible genomic medi-
cine educational content, resources and strategies.
These and other collaboratively-developed resources
supporting the use of genomic and pharmacogenomic
data to guide patient care are being made available in an
online “genomic medicine implementation toolkit” that
will be hosted on the IGNITE website in early 2016.
Discussion
Goals for collaborative research and the future of
genomic medicine
The IGNITE Network is poised to have a significant
impact on the acceleration of genomic information into
medical practice. The seven participating organizations
include significant expertise in translational research
and also have important linkages to health care delivery
systems, and patient and advocacy groups. In the short
term, each of the projects is defining novel implemen-
tation strategies that will eventually inform the broader
clinical community on how to bring genomic tools into
clinical workflows and health care. Specifically, IGNITE
will provide the standardized methods for implementa-
tion as well as the common measures to assess the im-
pact of implementation at the patient, provider and
health system level (e.g., satisfaction, feeling of well-
being, clinical outcomes, ability to help family mem-
bers). The network will also communicate the results to
a broad stakeholder community including regulators,
payers and patient and community groups. Because IG-
NITE projects involve diverse settings, it will be pos-
sible to identify specific modifications needed to bring
these innovative tools to underserved populations and a
variety of practice venues serving diverse populations.
Through affiliate members, IGNITE aspires to broaden
the range and repertoire of genomic interventions and
implementation strategies. Through its interactions
with other NHGRI networks that are working with gen-
omic tools and health care information and EHRs (such
as the eMERGE [Electronic Medical Records & Genom-
ics; https://emerge-network.org] Network and the CSER
[Clinical Sequencing Exploratory Research; https://cser-
consortium.org/] program), IGNITE will also provide
synergies to improve the application of genomics to
health care [2, 9]. In the long term, IGNITE seeks to
become a knowledge hub on implementation of gen-
omic medicine in the real world. It also aspires to de-
liver a tool box and know how – based on the Network’s
collective wisdom and insights – that others can use to
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integrate evidence-based genomic applications into
healthcare. With the recent announcement of the United
States’ Precision Medicine Initiative (wh.gov/precision-
medicine, http://www.nih.gov/precisionmedicine/), IG-
NITE can play a strategic role in assisting this effort to de-
liver on its goal to impact populations and eventually
population health (including educating providers and the
general public about precision medicine).
Conclusion
The IGNITE Network is a novel innovative collabora-
tive series of projects aiming to enhance the translation
of validated actionable genomic information into clin-
ical settings and thus create a road map for implemen-
tation with broad potential for use. IGNITE is also a
series of pilot demonstration projects that aim to de-
velop and use measures of outcome in response to
genome-based clinical interventions using a pragmatic
framework to provide early data and proofs of concept
on the utility of these interventions. IGNITE fills a crit-
ical gap in the translational genomics continuum in T3
(translation to practice) [6] research and will define for
many earlier stage genomic research projects a method-
ology and pathway for moving these findings into clinical
medicine. With the advent of the Precision Medicine Ini-
tiative as a national agenda, IGNITE’s mission and activ-
ities are timely and should provide important guidance to
the research and clinical community to enable more pre-
cise genome-informed medical care.
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